- Home
- IHD vs ATRA Comparison
IHD vs ATRA Comparison
Compare IHD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHD
- ATRA
- Stock Information
- Founded
- IHD 2011
- ATRA 2012
- Country
- IHD United States
- ATRA United States
- Employees
- IHD N/A
- ATRA N/A
- Industry
- IHD Investment Managers
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHD Finance
- ATRA Health Care
- Exchange
- IHD Nasdaq
- ATRA Nasdaq
- Market Cap
- IHD 108.0M
- ATRA 97.0M
- IPO Year
- IHD N/A
- ATRA 2014
- Fundamental
- Price
- IHD $6.28
- ATRA $10.93
- Analyst Decision
- IHD
- ATRA Strong Buy
- Analyst Count
- IHD 0
- ATRA 3
- Target Price
- IHD N/A
- ATRA $21.00
- AVG Volume (30 Days)
- IHD 27.7K
- ATRA 52.8K
- Earning Date
- IHD 01-01-0001
- ATRA 11-06-2025
- Dividend Yield
- IHD 10.32%
- ATRA N/A
- EPS Growth
- IHD N/A
- ATRA N/A
- EPS
- IHD N/A
- ATRA 0.56
- Revenue
- IHD N/A
- ATRA $188,667,000.00
- Revenue This Year
- IHD N/A
- ATRA N/A
- Revenue Next Year
- IHD N/A
- ATRA N/A
- P/E Ratio
- IHD N/A
- ATRA $21.82
- Revenue Growth
- IHD N/A
- ATRA 202.41
- 52 Week Low
- IHD $4.49
- ATRA $5.01
- 52 Week High
- IHD $5.47
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- IHD 48.22
- ATRA 32.98
- Support Level
- IHD $6.29
- ATRA $13.30
- Resistance Level
- IHD $6.40
- ATRA $15.30
- Average True Range (ATR)
- IHD 0.08
- ATRA 1.17
- MACD
- IHD -0.02
- ATRA -0.48
- Stochastic Oscillator
- IHD 24.43
- ATRA 2.22
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).